



VIA HAND DELIVERY OCTOBER 29TH, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: **RUBEN, et al.**

Application Number: 09/961,376

Group Art Unit: 1646

Filed: September 25, 2001

Examiner: Mertz, P.

Title: Human Tumor Necrosis Factor Receptor TR17

Atty. Docket No. PF524P1

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56 and 1.97(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys/Agents for Applicants hereby direct the Examiner's attention to references AA-AN listed on the attached revised form PTO/SB/08.

Copies of references AA-AN were submitted by Applicants or cited by the Examiner in connection with related U.S. Patent Application Serial No. 09/533,822 filed March 24, 2000, benefit of which is claimed under 35 U.S.C. § 120 by the instant application. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the above file for copies of references AA-AN.

Identification of the listed reference is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such

reference is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over the listed document should it be applied as a reference against the claims of the subject application.


The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. §1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed reference and that the reference be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(c), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. If Applicants are in error, please charge any additional required fees to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Date: October 29, 2003


Kenley K. Hoover (Reg. No. 40,302)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 610-5771

KKH/BM/lcc

Please type a plus sign (+) inside this box →



PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/961,376
				Filing Date	September 25, 2001
				First Named Inventor	RUBEN et al.
				Group Art Unit	1646
				Examiner Name	P. Mertz
Sheet	1	of	1	Attorney Docket Number	PF524P1

RECEIVED
NOV 05 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	5,969,102		St Jude Children's Research Hospital	10-19-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials ²	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	AB	WO	98/39361		St Jude Children's Research Hospital	09-11-1998		
	AC	WO	98/18921	A1	Human Genome Sciences	05-07-1998		
	AD	WO	00/40716		Zymogenetics, Inc.	07-13-2000		
	AE	WO	00/50597	A2	Human Genome Sciences	08-31-2000		
	AF	WO	00/58362	A1	Human Genome Sciences	10-05-2000		
	AG	WO	00/67034		Immunex Corp.	09-11-2000		

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	AH	VON BULOW et al., NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily.(1997) Science 278:138-141.		
	AI	GROOM et al., Association of BAFF/BLyS overexpression and altered B cells differentiation with Sjogren's Syndrome. <i>J Clin. Invest.</i> (2002) 109:59-68.		
	AJ	ZHANG et al., Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus. <i>J. Immunol.</i> (2001) 166:6-10.		
	AK	CHEEMA et al., Elevated Serum B Lymphocyte Stimulator Levels in Patients with Systemic Immune-Based Rheumatic Diseases, <i>Arthritis Rheum.</i> (2001) 44:1313-1319.		
	AL	MARRIETTE et al., A Role for B Lymphocyte Stimulator (TALL-1, BAFF, THANK, zTNF4) in Sjögren's Syndrome. 65 th Annual American College of Rheumatology Scientific Meeting. Nov. 2001.		
	AM	VAUX et al., The Buzz about BAFF. <i>J Clin. Invest.</i> (2002) 109:17-18.		
	AN	GROSS et al., TACI and BCMA are Receptors For a TNF Homologue Implicated In B-cell Autoimmune Disease. <i>Nature</i> (2000) 404:995-999.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.